Coronary Artery DiseasePhase 3NCT00042081
Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures
A Phase 3 study testing CGT003 (E2F Duplex Decoy) in people with Coronary Artery Disease, run by Anesiva, Inc. at 154 sites in United States.
Trial summary
The purpose of this study is to determine the efficacy of graft pretreatment with CGT003 (E2F Duplex Decoy), as compared to placebo, on the incidence of patients experiencing vein graft failure after coronary artery bypass surgery. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Coronary Artery Disease
- What is being tested?
- CGT003 (E2F Duplex Decoy)
- How many people
- 3,000 participants
- Where
- 154 sitesUnited States
- Study dates
- Jul 2002to Feb 2005
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
PATIENTS MUST:
- Have coronary artery disease and be scheduled to undergo a coronary artery bypass (CABG) procedure that is to include at least two segments of autogenous vein (sequential grafts do not count as two separate grafts).
- Be between 18 and 80 years old.
- Have a documented negative serum pregnancy test for all women of childbearing potential.
- Be using an acceptable method of birth control if of reproductive potential.
- Have agreed to participate voluntarily and signed and dated an IRB-approved, Patient Informed Consent form.
- (If one of the first 2400 patients enrolled) have agreed to participate voluntarily and signed and dated an IRB-approved, Patient Informed Consent form for the Angiography population.
- Note: Patients who are to receive an arterial bypass to the left anterior descending artery in addition to the two vein grafts required by the protocol ARE eligible for this study.
- Note: Patients ARE eligible for enrollment regardless of whether the planned procedure is to be on or off cardiopulmonary bypass pump.
- Note: Patients who do not wish to undergo elective Angiography at one year SHOULD NOT be enrolled in the first 2400 patients.
Trial locations and contacts
154 sites in 1 country.
154 sites in 1 country
United States154 sites
Akron General Medical Center
Akron, Ohio, 44307
Appleton Heart Institute at Appleton Medical Center
Appleton, Wisconsin, 54911
Crawford Long Hospital
Atlanta, Georgia, 30308
Emory University Hospital
Atlanta, Georgia, 30322
Florida Cardiovascular Research
Atlantis, Florida, 33462
JFK Medical Center
Atlantis, Florida, 33462
Heart Hospital of Austin
Austin, Texas, 78756
University of Maryland Medical Center
Baltimore, Maryland, 21201
Cardiac Surgery Associates
Baltimore, Maryland, 21215
Sinai Hospital of Baltimore
Baltimore, Maryland, 21215
Johns Hopkins Hospital
Baltimore, Maryland, 21287
St. Elizabeth's Hospital
Belleville, Illinois, 62220
Memorial Hospital
Belleville, Illinois, 62226
St. Joseph Hospital
Bellingham, Washington, 98225
St. Luke's Hospital
Bethlehem, Pennsylvania, 18015
Brookwood Medical Center
Birmingham, Alabama, 35209
Cardio-Thoracic Surgeons, P.C.
Birmingham, Alabama, 35209
Baptist Medical Center - Montclair
Birmingham, Alabama, 35213
Cardio-Thoracic Surgeons, P.C.
Birmingham, Alabama, 35213
Cardio-Thoracic Surgeons, P.C.
Birmingham, Alabama, 35235
Medical Center East
Birmingham, Alabama, 35235
Massachusetts General Hospital
Boston, Massachusetts, 02114
Brigham & Women's Hospital
Boston, Massachusetts, 02115
St. Vincent's Medical Center
Bridgeport, Connecticut, 06606
Aultman Health Foundation
Canton, Ohio, 44710
University of North Carolina Hospitals
Chapel Hill, North Carolina, 27154
Ambulatory Care Center
Chapel Hill, North Carolina, 27514
CAMC Health Education and Research Institute, Clinical Trials Center
Charleston, West Virginia, 25304
Charleston Area Medical Center
Charleston, West Virginia, 25304
Northwestern Medical Facility Foundation
Chicago, Illinois, 60611
Northwestern Memorial Hospital
Chicago, Illinois, 60611
Rush Presbyterian St. Luke's Medical Center
Chicago, Illinois, 60612
Rush Professional Building
Chicago, Illinois, 60612
Resurrection Medical Center
Chicago, Illinois, 60631
Cardiovascular & Thoracic Surgeons
Cincinnati, Ohio, 45220
Good Samaritan Hospital
Cincinnati, Ohio, 45220
Bethesda North Hospital
Cincinnati, Ohio, 45242
Cardiovascular & Thoracic Surgeons, Inc.
Cincinnati, Ohio, 45242
Morton Plant Hospital
Clearwater, Florida, 33756
The Ohio State University Medical Center
Columbus, Ohio, 43210
Riverside Methodist Hospital
Columbus, Ohio, 43214
Medical City Dallas Hospital
Dallas, Texas, 75230
Presbyterian Hospital of Dallas
Dallas, Texas, 75231
St. Paul University Hospital
Dallas, Texas, 75235
Seton Medical Center
Daly City, California, 94015
Genesis Heart Institute
Davenport, Iowa, 52803
Genesis Medical Center
Davenport, Iowa, 52803
Denton Regional Medical Center
Denton, Texas, 76210
Iowa Methodist Medical Center
Des Moines, Iowa, 50309
St. Mary's/Duluth Clinic Health System
Duluth, Minnesota, 55805
Duke University Medical Center
Durham, North Carolina, 27710
Evanston Northwestern Healthcare, Highland Park Hospital
Evanston, Illinois, 60201
Evanston Northwestern Healthcare
Evanston, Illinois, 60201
St. Francis Hospital of Evanston
Evanston, Illinois, 60202
MeritCare Clinic at MeritCare Hospital
Fargo, North Dakota, 58122
MeritCare Medical Group
Fargo, North Dakota, 58122
McLaren Regional Medical Center
Flint, Michigan, 48532
Gaston Memorial Hospital
Gastonia, North Carolina, 28054
Spectrum Health Hospitals
Grand Rapids, Michigan, 49503
Pitt County Memorial Hospital
Greenville, North Carolina, 27834
Brody School of Medicine, East Carolina University
Greenville, North Carolina, 27858
Greenville Hospital System
Greenville, South Carolina, 29605
Upstate Cardiothoracic Surgery, Greenville Hospital System
Greenville, South Carolina, 29605
Forrest General Hospital
Hattiesburg, Mississippi, 39401
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033
St. Vincent Hospital and Health Care Service
Indianapolis, Indiana, 46260
The Heart Center of Indiana
Indianapolis, Indiana, 46290
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242
St. John's Regional Medical Center
Joplin, Missouri, 64804
930 Carondelet Drive
Kansas City, Missouri, 64114
Kettering Medical Center Network, Kettering Hospital
Kettering, Ohio, 45429
Ingham Regional Medical Center
Lansing, Michigan, 48910
Thoracic & Cardiovascular Healthcare Foundation
Lansing, Michigan, 48910
Thoracic & Cardiovascular Institute
Lansing, Michigan, 48910
Cedars-Sinai Medical Center
Los Angeles, California, 90048
Jewish Hospital Health Care Services
Louisville, Kentucky, 40202
Lynchburg General Hospital
Lynchburg, Virginia, 24501
Loyola University Chicago Medical Center
Maywood, Illinois, 60153
Holmes Regional Medical Center
Melbourne, Florida, 32901
Saint Francis Hospital
Memphis, Tennessee, 38119
St. Luke's Medical Center
Milwaukee, Wisconsin, 53215
Abbott Northwestern Hospital
Minneapolis, Minnesota, 55407
Park Nicollet Institute
Minneapolis, Minnesota, 55416
Morristown Memorial Hospital
Morristown, New Jersey, 07962
Edward Hospital & Health Services
Naperville, Illinois, 60540
Robert Wood Johnson University Hospital
New Brunswick, New Jersey, 08903
Umdnj-Rwjms
New Brunswick, New Jersey, 08903
Lenox Hill Hospital
New York, New York, 10021
New York Presbyterian Medical Center, Milstein Hospital Building
New York, New York, 10032
Sentara Norfolk General Hospital
Norfolk, Virginia, 23507
Mid-Atlantic Cardiothoracic Surgeons, Ltd.
Norfolk, Virginia, 23510
Advocate Christ Hospital and Medical Center
Oak Lawn, Illinois, 60453
Nebraska Methodist Hospital
Omaha, Nebraska, 68114
Nebraska Heart Institute
Omaha, Nebraska, 68131
University of Nebraska Medical Center
Omaha, Nebraska, 68131
Cardiovascular Surgeons, P.A.
Orlando, Florida, 32801
Florida Hospital
Orlando, Florida, 32803
Orlando Cardiovascular Center, LLLP
Orlando, Florida, 32806
Orlando Heart Center
Orlando, Florida, 32806
Orlando Regional Med Center
Orlando, Florida, 32806
Orlando Heart Center/Sand Lake
Orlando, Florida, 32819
Georgetown Professional Plaza
Overland Park, Kansas, 66204
Desert Regional Medical Center
Palm Springs, California, 92262
Nebraska Heart Institute
Papillion, Nebraska, 68046
OSF St. Francis Medical Center
Peoria, Illinois, 61637
Cardiology Consultants, PC
Petoskey, Michigan, 49770
Great Lakes Cardiothoracic and Vascular Surgery
Petoskey, Michigan, 49770
Northern Michigan Hospital
Petoskey, Michigan, 49770
Petoskey Cardiology
Petoskey, Michigan, 49770
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104
Presbyterian Hospital, University of Pennsylvania Health System
Philadelphia, Pennsylvania, 19104
FirstHealth Moore Regional Hospital
Pinehurst, North Carolina, 28374
Allegheny General Hospital
Pittsburgh, Pennsylvania, 15212
University of Pittsburgh Medical Center, Presbyterian Hospital
Pittsburgh, Pennsylvania, 15213
Medical Center Plano
Plano, Texas, 75075
Maine Medical Center
Portland, Maine, 04102
The Valley Hospital
Ridgewood, New Jersey, 07450
Michigan Cardiovascular Institute
Saginaw, Michigan, 48601
Convenant Medical Center
Saginaw, Michigan, 48602
Methodist Hospital
Saint Louis Park, Minnesota, 55426
Park Nicollet Heart Center
Saint Louis Park, Minnesota, 55426
Peninsula Regional Medical Center
Salisbury, Maryland, 21801
University of Utah Health Sciences Center
Salt Lake City, Utah, 84132
Southwest Texas Methodist Hospital
San Antonio, Texas, 78229
Northeast Methodist Hospital
San Antonio, Texas, 78233
Clinical Research Center
Sarasota, Florida, 34239
Sarasota Memorial Health Care System
Sarasota, Florida, 34239
Guthrie Clinic
Sayre, Pennsylvania, 18840
Robert Packer Hospital
Sayre, Pennsylvania, 18840
Shawnee Mission Medical Center
Shawnee Mission, Kansas, 66204
Deaconess Medical Center
Spokane, Washington, 99204
Northwest Heart and Lung Surgical Associates
Spokane, Washington, 99204
Memorial Medical Center
Springfield, Illinois, 62702
Southern Illinois University School of Medicine, Dep. of Surgery, Div. of Cardiothoracic Surgery
Springfield, Illinois, 62702
Southern Illinois University School of Medicine, Department of Surgery, Division of Cardiothoracic Surgery
Springfield, Illinois, 62702
St. John's Hospital
Springfield, Illinois, 62702
Baystate Medical Center
Springfield, Massachusetts, 01199
Missouri Baptist Medical Center
St Louis, Missouri, 63131
St. Joseph's Medical Center
Stockton, California, 95204
Washington Adventist Hospital
Takoma Park, Maryland, 20912
St. Vincent Mercy Medical Center
Toledo, Ohio, 43608
Cardiac Surgery Associates
Towson, Maryland, 21204
Midatlantic Cardiovascular Associates, P.A.
Towson, Maryland, 21204
St. Joseph Medical Center
Towson, Maryland, 21204
Westchester Medical Center
Valhalla, New York, 10595
Washington Hospital Center
Washington D.C., District of Columbia, 20010
Waukesha Memorial Hospital
Waukesha, Wisconsin, 53188
Community Health Care/Wausau Hospital
Wausau, Wisconsin, 54401
Wausau Heart and Lung Surgeons
Wausau, Wisconsin, 54401
The Chester County Hospital
West Chester, Pennsylvania, 19380
Central DuPage Hospital
Winfield, Illinois, 60190
Forysyth Medical Center
Winston-Salem, North Carolina, 27103
Walley, Morgan & Duncan, M.D., P.A.
Winston-Salem, North Carolina, 27103
Lankenau Hospital
Wynnewood, Pennsylvania, 19096
About this study
Official title: A Phase III, Multi-Center Randomized, Double-Blind, Placebo-Controlled Trial of the Ex Vivo Treatment With CGT003 of Coronary Vein Grafts in Patients Undergoing Coronary Artery Bypass Graft Procedures
The purpose of this study is to determine the efficacy of graft pretreatment with CGT003 (E2F Duplex Decoy), as compared to placebo, on the incidence of patients experiencing vein graft failure after coronary artery bypass surgery.
Read the detailed description
Coronary vascular disease manifested by narrowing of the coronary arteries is one of the more common manifestations of atherosclerotic vascular disease. The clinical manifestations of coronary artery disease include death, angina pectoris, myocardial infarction, congestive heart failure and arrhythmia. Restoration of circulation to the heart may be undertaken using a variety of techniques including angioplasty, stenting, and bypass grafting.
Approximately 359,000 patients underwent coronary bypass procedures in the U.S. in 1999. Long term studies have observed an incidence of vein graft occlusion at 19% at 1 year, 25% at 5 years and 50% by 15 years after operation for an overall rate of 2.5% per year after the first year of observation. The consequences of graft failure are as significant as those of primary atherosclerotic disease and include ischemia, myocardial infarction and death.
CGT003 is a novel therapeutic that is under investigation as a treatment to prevent vein graft failure. It acts by inhibiting the transcription factor, E2F, which is activated in response to injury such as that which occurs when thin-walled vein grafts are exposed to the pressures of the arterial circulation. Blockade of E2F inhibits smooth muscle cell proliferation and redirects the vein graft remodeling that occurs within the first several days after implantation towards medial hypertrophy and strengthening of the medial layer and blunts formation of neointima. Inhibition of neotinimal formation coupled with expansion of the media should result in a decreased risk of the accelerated atherosclerosis and consequent vein graft failure over several years.
- Conditions
- Coronary Artery Disease
- Being tested
- CGT003 (E2F Duplex Decoy)
- Keywords
- CABG, coronary artery bypass surgery, coronary artery disease, coronary arteriosclerosis, coronary stenosis, coronary occlusion
- Medical subject headings
- Coronary Artery Disease, Coronary Stenosis, Coronary Occlusion
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CGT003 (E2F Duplex Decoy)Drug
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jul 2002 (estimated)
- Study startJul 2002
- Study completionFeb 2005
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind
- Enrolment
- 3,000 participants
Sponsor and investigators
- Lead sponsor
- Anesiva, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Todd Lorenz, M.D., Study director, Anesiva, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00042081
- Sponsor's protocol ID
- CGT003-04
- Status last verified
- Jul 2005
- First submitted
- 22 Jul 2002
- Last updated
- 5 May 2006
- Results posted
- No
Publications
Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT; PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005 Nov 16;294(19):2446-54. doi: 10.1001/jama.294.19.2446.
PubMed 16287955Harskamp RE, Alexander JH, Ferguson TB Jr, Hager R, Mack MJ, Englum B, Wojdyla D, Schulte PJ, Kouchoukos NT, de Winter RJ, Gibson CM, Peterson ED, Harrington RA, Smith PK, Lopes RD. Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial. Circulation. 2016 Jan 12;133(2):131-8. doi: 10.1161/CIRCULATIONAHA.115.015549. Epub 2015 Dec 8.
PubMed 26647082Hess CN, Lopes RD, Gibson CM, Hager R, Wojdyla DM, Englum BR, Mack MJ, Califf RM, Kouchoukos NT, Peterson ED, Alexander JH. Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV. Circulation. 2014 Oct 21;130(17):1445-51. doi: 10.1161/CIRCULATIONAHA.113.008193. Epub 2014 Sep 26.
PubMed 25261549Harskamp RE, Alexander JH, Schulte PJ, Brophy CM, Mack MJ, Peterson ED, Williams JB, Gibson CM, Califf RM, Kouchoukos NT, Harrington RA, Ferguson TB Jr, Lopes RD. Vein graft preservation solutions, patency, and outcomes after coronary artery bypass graft surgery: follow-up from the PREVENT IV randomized clinical trial. JAMA Surg. 2014 Aug;149(8):798-805. doi: 10.1001/jamasurg.2014.87.
PubMed 25073921Lopes RD, Williams JB, Mehta RH, Reyes EM, Hafley GE, Allen KB, Mack MJ, Peterson ED, Harrington RA, Gibson CM, Califf RM, Kouchoukos NT, Ferguson TB, Lorenz TJ, Alexander JH. Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. Am Heart J. 2012 Sep;164(3):379-386.e1. doi: 10.1016/j.ahj.2012.05.019.
PubMed 22980305
Study at a glance
From the registry record, last updated by the sponsor on 5 May 2006. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase III, Multi-Center Randomized, Double-Blind, Placebo-Controlled Trial of the Ex Vivo Treatment With CGT003 of Coronary Vein Grafts in Patients Undergoing Coronary Artery Bypass Graft Procedures
- ClinicalTrials.gov ID
- NCT00042081
- Acronym / sponsor ID
- CGT003-04
- Conditions
- Coronary Artery Disease
- Keywords
- CABG, coronary artery bypass surgery, coronary artery disease, coronary arteriosclerosis, coronary stenosis, coronary occlusion
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 3,000 participants
- Lead sponsor
- Anesiva, Inc.Industry (pharma, biotech, devices)
- Study start
- Jul 2002
- Study completion
- Feb 2005
- First posted
- 24 Jul 2002 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine the efficacy of graft pretreatment with CGT003 (E2F Duplex Decoy), as compared to placebo, on the incidence of patients experiencing vein graft failure after coronary artery bypass surgery.
Detailed description
Coronary vascular disease manifested by narrowing of the coronary arteries is one of the more common manifestations of atherosclerotic vascular disease. The clinical manifestations of coronary artery disease include death, angina pectoris, myocardial infarction, congestive heart failure and arrhythmia. Restoration of circulation to the heart may be undertaken using a variety of techniques including angioplasty, stenting, and bypass grafting.
Approximately 359,000 patients underwent coronary bypass procedures in the U.S. in 1999. Long term studies have observed an incidence of vein graft occlusion at 19% at 1 year, 25% at 5 years and 50% by 15 years after operation for an overall rate of 2.5% per year after the first year of observation. The consequences of graft failure are as significant as those of primary atherosclerotic disease and include ischemia, myocardial infarction and death.
CGT003 is a novel therapeutic that is under investigation as a treatment to prevent vein graft failure. It acts by inhibiting the transcription factor, E2F, which is activated in response to injury such as that which occurs when thin-walled vein grafts are exposed to the pressures of the arterial circulation. Blockade of E2F inhibits smooth muscle cell proliferation and redirects the vein graft remodeling that occurs within the first several days after implantation towards medial hypertrophy and strengthening of the medial layer and blunts formation of neointima. Inhibition of neotinimal formation coupled with expansion of the media should result in a decreased risk of the accelerated atherosclerosis and consequent vein graft failure over several years.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CGT003 (E2F Duplex Decoy) | Drug | – |
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 May 2006.
- Results publication: PubMed 16287955Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT; PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005 Nov 16;294(19):2446-54. doi: 10.1001/jama.294.19.2446.
- Derived from this study: PubMed 26647082Harskamp RE, Alexander JH, Ferguson TB Jr, Hager R, Mack MJ, Englum B, Wojdyla D, Schulte PJ, Kouchoukos NT, de Winter RJ, Gibson CM, Peterson ED, Harrington RA, Smith PK, Lopes RD. Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial. Circulation. 2016 Jan 12;133(2):131-8. doi: 10.1161/CIRCULATIONAHA.115.015549. Epub 2015 Dec 8.
- Derived from this study: PubMed 25261549Hess CN, Lopes RD, Gibson CM, Hager R, Wojdyla DM, Englum BR, Mack MJ, Califf RM, Kouchoukos NT, Peterson ED, Alexander JH. Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV. Circulation. 2014 Oct 21;130(17):1445-51. doi: 10.1161/CIRCULATIONAHA.113.008193. Epub 2014 Sep 26.
- Derived from this study: PubMed 25073921Harskamp RE, Alexander JH, Schulte PJ, Brophy CM, Mack MJ, Peterson ED, Williams JB, Gibson CM, Califf RM, Kouchoukos NT, Harrington RA, Ferguson TB Jr, Lopes RD. Vein graft preservation solutions, patency, and outcomes after coronary artery bypass graft surgery: follow-up from the PREVENT IV randomized clinical trial. JAMA Surg. 2014 Aug;149(8):798-805. doi: 10.1001/jamasurg.2014.87.
- Derived from this study: PubMed 22980305Lopes RD, Williams JB, Mehta RH, Reyes EM, Hafley GE, Allen KB, Mack MJ, Peterson ED, Harrington RA, Gibson CM, Califf RM, Kouchoukos NT, Ferguson TB, Lorenz TJ, Alexander JH. Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. Am Heart J. 2012 Sep;164(3):379-386.e1. doi: 10.1016/j.ahj.2012.05.019.
Related trials for Coronary Artery Disease
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Todd Lorenz, M.D. study director
Anesiva, Inc.
154 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing CGT003 (E2F Duplex Decoy) in people with Coronary Artery Disease, run by Anesiva, Inc. at 154 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 May 2006. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 154 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00042081, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2006.